Skip to main content
ONCIMMUNE HOLDINGS PLC logo

ONCIMMUNE HOLDINGS PLC — Investor Relations & Filings

Ticker · ONC ISIN · GB00BYQ94H38 LEI · 213800HCYIWT6YPI1I02 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2024-09-02 Regulatory Filings
Country GB United Kingdom
Listing IL ONC

About ONCIMMUNE HOLDINGS PLC

https://www.oncimmune.com/

Oncimmune Holdings PLC is a precision medicine and immunodiagnostics company specializing in the discovery and application of antibody and autoantibody biomarker signatures. The company's core technology is the ImmunoINSIGHTS™ platform, an advanced analytical engine for immune profiling. This platform utilizes a proprietary library of over 9,000 human antigens, bead-based multiplexed immunoassay technology, and machine learning algorithms to generate biological insights from minimal sample volumes. Oncimmune applies its expertise across therapeutic areas including immuno-oncology, autoimmune diseases, and infectious diseases. It provides biomarker discovery services, targeted panels, and advanced bioinformatics to support pharmaceutical and biotechnology partners in developing more effective and targeted treatments and diagnostics.

Recent filings

Filing Released Lang Actions
Contract Win
Regulatory Filings Classification · 98% confidence The document starts with an 'RNS Number' and is dated 02 September 2024. It announces a new contract win ('Additional contract win with Top 10 Pharma Company') and includes standard boilerplate language from RNS (London Stock Exchange's news service) at the end, explicitly stating: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory announcement disseminated via the RNS system, which serves as a primary information provider for the UK market. Since the content is a specific business update (contract win) and not a formal financial report (like 10-K or IR), nor a specific corporate action like a dividend or director dealing, the most appropriate classification is the general regulatory announcement category, RNS.
2024-09-02 English
US$1.5m Contract Win with Top 10 Pharma Company
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' header and is dated '09 August 2024'. It announces a significant new contract win ('US$1.5m Contract Win with Top 10 Pharma Company') and provides financial guidance updates for FY2024 and FY2025. The text concludes with standard disclaimers referencing 'RNS, the news service of the London Stock Exchange' and 'Market Abuse Regulation'. This structure is characteristic of a regulatory news service announcement, which is the general category for miscellaneous regulatory filings not covered by more specific codes like 10-K, ER, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document is not a full report (like 10-K or IR) but a brief announcement of material news.
2024-08-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 6046T' and contains the standard format for a regulatory notification from the London Stock Exchange's news service (RNS). The content details a 'TR-1: Standard form for notification of major holdings' regarding an acquisition/disposal of financial instruments by Spreadex LTD, crossing a voting rights threshold. This type of filing, which reports changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-06-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange's news service. The content is a 'TR-1: Standard form for notification of major holdings' concerning an acquisition/disposal of financial instruments by a shareholder (Spreadex LTD), detailing changes in voting rights percentages. This type of mandatory disclosure regarding significant changes in share ownership thresholds falls under the category of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-06-17 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 3484Q' on '29 May 2024'. It details changes in voting rights held by a shareholder ('Spreadex LTD') crossing a notification threshold, specifically reporting on the acquisition or disposal of financial instruments (CFDs/Spreadbets). This structure perfectly matches the definition of a Major Shareholding Notification, which is categorized under the code MRQ in the provided schema, as it reports changes in significant share ownership levels crossing thresholds.
2024-05-29 English
Interim Results
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Results' announcement for Oncimmune Holdings plc for the six months ended 29 February 2024. It contains comprehensive financial statements, including a consolidated income statement, statement of financial position, and statement of cash flows. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). H1 2024
2024-05-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.